Table I.
NIP1 Type | Binding
|
H+-ATPase Stimulation
|
Elicitor Activity
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Kd, Ki | Ratioa | EC50 | Emaxb | IRAc | IREd | EC50 | Emaxb | IRAc | IREd | |
nm | μm | % | μm | PI Units | ||||||
I | 5.6e | 2.35 | 61.2 | 1.82 | 0.22 | 1.06 × 105 | 8.94 | |||
II | 734f | 130 | 2.86 | 40.9 | 72.0 | 2.14 | 1.15 × 105 | 14.7 | ||
III | Approximately 730f,g | – | – | |||||||
IV | Approximately 730f,g | – | – | |||||||
III* | 13.7f | – | – | |||||||
IV* | 6.8f | – | – |
Ki type II/Kd type I.
Maximal response: stimulation of the H+-ATPase (% of unstimulated activity), PR5 mRNA accumulation (phosphoimager [PI] units).
Intrinsic relative activity.
Intrinsic relative efficacy:intrinsic efficacy (ɛ) of type II expressed relative to that of type I.
Kd.
Ki.
Expected.